Key result
GLP-1 RA therapy is linked to weight loss and increased resting HR driven by reduced HRV.
Why the study?
Does GLP-1 RA therapy alter resting heart rate, heart rate variability, and physical activity over 12 weeks?
Observational
Does GLP-1 RA therapy alter resting heart rate, heart rate variability, and physical activity over 12 weeks?
GLP-1 RA initiation is associated with substantial weight loss but also significant increases in resting heart rate mediated by reduced heart rate variability, which may be tempered by increased physical activity.
May warrant resting heart rate monitoring with GLP-1 RA initiation; hypothesis-generating for HRV mediation and activity effects.
These findings are among the first to provide daily insights into cardiovascular and behavioral responses following GLP-1 RA initiation. Substantial weight loss and significant increases in resting heart rate mediated by reductions in heart rate variability during the initial 12 wk of GLP-1 RA therapy were observed. In addition, trends suggest an increase in physical activity with GLP-1 therapy, and that physical activity may help to temper GLP-1 RA-associated increases in resting heart rate.
No takes yet. Share an insight, caveat, or question.
Grosicki et al. (2024) reported an observational. GLP-1 receptor agonists was evaluated on Cardiovascular and behavioral responses (weight loss, resting heart rate, heart rate variability). GLP-1 RA therapy over 12 weeks was associated with substantial weight loss and significant increases in resting heart rate mediated by reductions in heart rate variability.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: